What the Yale Secret Shopper Study Means for Your Next Prescription
A JAMA-published secret shopper study made headlines in early July 2026: researchers posing as patients found that 45 of 49 telehealth platforms offering GLP-1 medications prescribed with minimal clinical oversight, and roughly two-thirds involved zero direct interaction with a clinician before a prescription was issued. If you're about to start or continue GLP-1 treatment through telehealth, here's what the study actually means for your next appointment.
What the study found
The researchers' core finding wasn't that telehealth GLP-1 prescribing is inherently unsafe — it's that oversight varies enormously between platforms, and a platform's marketing rarely tells you which category it falls into. Some providers had thorough, physician-reviewed intake with follow-up scheduling built in. Others approved prescriptions almost automatically off a questionnaire, with no meaningful clinical judgment applied.
What this means for your next prescription
It means the burden of verification shifts to you. Before your next telehealth visit — whether it's your first or a refill — a few questions are worth asking directly:
- Will an actual physician or nurse practitioner review my intake, or does approval happen automatically?
- Is there a scheduled follow-up, or does the relationship end once medication ships?
- What happens if I report a side effect — is there a real person to message?
A provider that answers these clearly and specifically is behaving differently than one that gives a vague, marketing-forward answer.
Providers with documented clinical follow-up
Eden Health From $196
Holistic weight management with LegitScript certification and a direct intake process. Includes documented follow-up rather than a one-time transaction.
Visit Eden Health →Paid linkSesame Care From $44
A transparent marketplace prescribing FDA-approved brand-name medications, with a wide network of licensed providers and no membership fees.
The honest takeaway
The study is a legitimate wake-up call, not a reason to avoid telehealth GLP-1 care altogether — for many patients, it's still the most accessible path to treatment. The fix isn't switching to a different delivery model; it's asking sharper questions of whichever provider you choose, and treating "how thorough was my evaluation" as a real selection criterion, not an afterthought.